Efficacy of tofacitinib for the treatment of psoriatic arthritis: pooled analysis of two phase 3 studies
Introduction Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). This post hoc analysis assessed the efficacy of tofacitinib using pooled data from two phase 3 studies of patients with active PsA.
Methods Data were pooled from OPAL Broaden (NCT01877668) and OPAL Beyond (NCT01882439). Patients had active PsA and either an inadequate response (IR) to ≥ 1 conventional synthetic disease-modifying antirheumatic ... Expand abstract
- Publication status:
- Peer review status:
- Peer reviewed
- Publisher's Version
- Springer Nature Publisher's website
- Rheumatology and Therapy Journal website
- Publication date:
- Acceptance date:
- Pubs id:
- Local pid:
- Copyright holder:
- Nash et al.
- Copyright date:
- © The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Views and Downloads
If you are the owner of this record, you can report an update to it here: Report update to this record